The ABPI is delighted to announce that it will now represent the vaccine industry to Government and healthcare stakeholders.
A new ABPI Vaccine Group has been formed today and will work in partnership with the public health community to support the development and implementation of successful UK immunisation programmes. The group is made up of six members - Abbott Healthcare Products Ltd, AstraZeneca, GSK, Janssen, Novartis, Pfizer.
UVIG, which has represented the vaccine industry for over a decade, has been disbanded.
Vaccinations are important because they protect the public from preventable disease, thereby helping save lives and prevent ill health whilst minimising the costs to the health service of non-immunisation. According to the World Health Organisation, vaccines help to prevent more than 2.5 million deaths each year across the world that would otherwise occur without vaccination.
Stephen Whitehead, Chief Executive of the ABPI, said:
"I am delighted that the ABPI will be taking a leading role in representing the vaccines industry to Government and other healthcare stakeholders. This addition to the ABPI strengthens the unity of the bio-pharmaceutical industry and further underlines the ABPI’s position as the leading life sciences trade association in the UK. Vaccinations against disease play a vital role in improving public health and help protect us from preventable illnesses. I am immensely proud of the work pharmaceutical companies do to bring these medicines to people across the world."
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: [email protected]
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.